Medical Moment One: Novel Pharmacologic Approaches in a Symptomatic, High-risk HFrEF Patient Population
Join Drs. Muthiah Vaduganathan and Javed Butler for this on-demand online activity, as they examine novel methodologies to address the clinical worsening of HFrEF, with a focus on recently-reported results from the VICTORIA trial.
Category
  • Cardiology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
Medical Moment Two: Multifaceted Challenges in Medical Therapy Optimization during Episodes of Worsening HFrEF
Initiating and optimizing in-hospital guideline-directed medical therapies (GDMT) remains a challenge for clinicians treating patients with worsening HFrEF. Join Drs.
Category
  • Cardiology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
New Horizons in Ovarian Cancer: Expert Insights into the Role of Genetic Biomarkers in Precision Therapy
Attendees of these regional meetings will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as th
Category
  • Oncology
Format
  • Online live
Credits
  • AMA PRA Category 1 Credit™
  • Participation
Event date September 25, 2021
Navigating the Patient Journey in Chronic Lymphocytic Leukemia: Oncology Nurse Strategies in Therapy Management
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies fo
Category
  • Oncology
Format
  • Online live
Credits
  • ANCC
  • Participation
3rd ANNUAL EGFR RESISTERS RESEARCH SUMMIT
To complete your submission:
Category
  • Oncology
Format
  • Conference / meeting
  • Online live
Credits
Event date November 13, 2021
Paving the Way to Novel Therapies in CLL: Real World Patient Cases for the Oncology Pharmacist
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for
Category
  • Oncology
Format
  • Online live
Credits
  • ACPE Pharmacy
  • Participation
Event date September 23, 2021
Navigating the Patient Journey in Chronic Lymphocytic Leukemia: Oncology Nurse Strategies in Therapy Management
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies fo
Category
  • Oncology
Format
  • Online live
Credits
  • ANCC
  • Participation
Event date September 22, 2021
Navigating the Patient Journey in Chronic Lymphocytic Leukemia: Oncology Nurse Strategies in Therapy Management
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies fo
Category
  • Oncology
Format
  • Online live
Credits
  • ANCC
  • Participation
Event date September 30, 2021
Navigating Evolving Paradigms in B-cell Malignancies: Latest Insights and Novel Approaches for The Oncology Care Team
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.
Category
  • Oncology
Format
  • Online live
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Event date October 1, 2021
2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation

Pages